European Network for Health Technology Assessment

The European Network for Health Technology Assessment, commonly known as EUnetHTA, is a European collaboration network focused on strengthening health technology assessment (HTA). HTA is the multidisciplinary process used to examine the clinical, economic, organizational, social, ethical, and broader policy implications of health technologies, including medicines, medical devices, diagnostics, procedures, and healthcare systems. EUnetHTA was established to help create an effective and sustainable structure for HTA cooperation across Europe rather than to operate as a commercial healthcare supplier or a single national assessment authority. Its central purpose is to connect public national and regional HTA agencies, research institutions, and health ministries. Through this network, participating organizations can exchange information, coordinate assessment methods, develop common tools, and reduce duplication in the production of evidence. The intended result is that Member States have access to information that is objective, reliable, timely, transparent, and sufficiently comparable for reuse in national and regional HTA work. EUnetHTA therefore supports evidence-based and more consistent decisions about the adoption, reimbursement, procurement, and use of health technologies. The network’s work has been organized through successive European cooperation programmes. Joint Action 1 ran from 2010 to 2012 and established an initial framework for coordinated HTA activity. Joint Action 2 continued this work from 2012 to 2015, developing a broader strategy, shared principles, and an implementation proposal for sustainable European HTA collaboration. This work was linked to the requirements of Article 15 of the European Union Directive on the application of patients’ rights in cross-border healthcare. Joint Action 3, covering 2016 to 2021, sought to increase the use, quality, and efficiency of joint HTA work at European level. The later EUnetHTA 21 initiative, running from 2021 to 2023, built on the methods and lessons of the earlier Joint Actions and supported preparations for a future European Union HTA system under the EU HTA Regulation. These programmes represent an evolution from voluntary information exchange toward more structured and potentially permanent European cooperation. EUnetHTA has also developed a governance model intended to include stakeholders beyond assessment agencies and government bodies. Its annual Forum provides a mechanism for engagement with patient and healthcare consumer organizations, healthcare providers, payers such as statutory health insurers, and industry representatives. This structure recognizes that HTA conclusions affect multiple groups and that the legitimacy of assessment depends not only on technical quality but also on transparency and stakeholder participation. The network has been described as comprising 83 organizations from 27 EU Member States, together with organizations from Norway, Switzerland, Ukraine, and the United Kingdom. Its operating model emphasizes voluntary cooperation, transferability of evidence, and adaptation of joint outputs to national decision-making environments. Because healthcare systems, reimbursement rules, and institutional responsibilities differ between countries, EUnetHTA does not replace national HTA decisions. Instead, it provides a collaborative evidence and methodological infrastructure intended to make those decisions more efficient, comparable, and informed. EUnetHTA’s identity is therefore institutional and public-policy oriented. It is best understood as a transnational professional and technical network rather than a conventional consumer brand. Its principal outputs are methodological frameworks, assessment processes, shared information, guidance, and collaborative work products that support healthcare authorities and assessment organizations. The network’s longer-term significance lies in its contribution to European cooperation on the evaluation of health technologies and to the development of a common foundation for EU-level HTA.

EUnetHTA emerged from the need for closer European cooperation in health technology assessment. National and regional HTA bodies often evaluate similar medicines, medical devices, diagnostics, procedures, and healthcare interventions, but they operate within different legal, institutional, economic, and clinical environments. Without coordination, comparable evidence may be assessed repeatedly, while methods and reporting formats can vary. EUnetHTA was created to address this fragmentation by connecting public HTA agencies, research institutions, and health ministries and by developing practical mechanisms for sharing and reusing evidence. The network’s strategic objective has been to establish an effective and sustainable European structure for HTA collaboration. Its approach is not to impose a single assessment decision on all participating countries. Instead, EUnetHTA develops information and methods that can be transferred, adapted, and reused by Member States in their own national or regional processes. This distinction is important because healthcare priorities, reimbursement arrangements, budgets, and decision-making powers remain different across Europe. The first EUnetHTA Joint Action ran from 2010 to 2012 and provided an initial platform for coordinated work. Joint Action 2 began on 1 October 2012 and continued through 2015. It developed a general strategy, shared principles, and an implementation proposal for sustainable European HTA cooperation. Its activities were associated with Article 15 of the European Union Directive concerning patients’ rights in cross-border healthcare, which created a policy context for cooperation among national authorities. Joint Action 3 followed from 2016 to 2021. Its emphasis was on increasing the use, quality, and efficiency of joint HTA activities at European level. This phase reflected a move from establishing a network and common concepts toward producing work that could be used more routinely by national and regional assessment bodies. The network’s stated goals included supporting evidence-based, sustainable, and equitable choices in healthcare and improving the reliability and timeliness of information available to decision-makers. From 2021 to 2023, EUnetHTA 21 built on the experience of the earlier Joint Actions. Its work was directed toward supporting a future EU HTA system under the European Union’s HTA Regulation. This phase represented a further institutional development of European cooperation, with voluntary network-based collaboration providing experience and practical foundations for a more structured EU framework. EUnetHTA’s membership and governance have extended beyond government agencies alone. The network has been described as comprising 83 organizations from 27 EU Member States as well as Norway, Switzerland, Ukraine, and the United Kingdom. Its annual Forum was established to support transparent engagement with patient and healthcare consumer groups, healthcare providers, statutory health-insurance payers, and industry. Such participation provides a channel for different stakeholders to contribute perspectives on evidence needs, implementation, patient relevance, and the practical consequences of HTA findings. Across its successive programmes, EUnetHTA has concentrated on methodological cooperation, information exchange, assessment coordination, and the reuse of outputs. Its work supports decision-makers who must determine whether and how health technologies should be adopted, funded, or incorporated into healthcare delivery. The network’s role is therefore infrastructural: it helps make HTA more coordinated and comparable while leaving final policy and reimbursement decisions to the competent authorities in participating systems. EUnetHTA is best characterized as a European professional and public-policy network rather than a conventional commercial brand. Its value is expressed through shared methods, collaborative assessments, stakeholder processes, and the institutional relationships that make cross-border evidence cooperation possible. The network’s successive Joint Actions and EUnetHTA 21 programme document a gradual transition from exploratory collaboration to support for a more permanent European HTA architecture.

• 2023

  EUnetHTA 21 programme period ends

  [1]European Network for Health Technology Assessmenten.wikipedia.org

  The stated EUnetHTA 21 programme period concluded after its work on the transition toward a future European Union HTA system.

• 2021

  EUnetHTA 21 begins

  [1]European Network for Health Technology Assessmenten.wikipedia.org

  EUnetHTA 21 started a new phase focused on building on earlier Joint Actions and supporting the future EU HTA system under the HTA Regulation.

• 2016

  Joint Action 3 begins

  [1]European Network for Health Technology Assessmenten.wikipedia.org

  The third Joint Action began with an emphasis on improving the use, quality, and efficiency of joint HTA work at European level.

• 2015

  Joint Action 2 concludes

  [1]European Network for Health Technology Assessmenten.wikipedia.org

  The second Joint Action completed its programme of work on European HTA strategy, principles, and implementation planning.

• 2012

  Joint Action 2 starts

  [1]European Network for Health Technology Assessmenten.wikipedia.org

  Joint Action 2 began on 1 October 2012, continuing the first programme and developing a strategy, principles, and implementation proposal for sustainable European HTA collaboration.

• 2010

  EUnetHTA Joint Action 1 begins

  [1]European Network for Health Technology Assessmenten.wikipedia.org

  The first Joint Action established an initial framework for coordinated health technology assessment cooperation in Europe.

A public-interest European HTA collaboration network that improves the consistency, efficiency, transparency, and transferability of evidence used in healthcare policy decisions.

• Health technology assessment

  Joint HTA work

  Collaborative assessment activities that bring together European HTA organizations to examine health technologies and produce evidence that can inform national or regional decision-making. The work is intended to reduce duplicated effort while allowing participating authorities to adapt findings to their own healthcare systems, legal frameworks, and policy requirements.

• Methodological guidance

  HTA methods and practical tools

  Shared approaches, principles, and practical tools designed to improve the consistency, transparency, reliability, and transferability of health technology assessment across Europe. These materials support agencies and other public bodies in producing and interpreting HTA information.

• Professional information network

  European HTA information exchange

  A network-based information infrastructure linking public HTA agencies, research institutions, and health ministries. It facilitates the exchange and potential reuse of HTA-relevant evidence in national and regional reports and activities.

• Stakeholder engagement

  Annual Forum

  A governance and engagement forum intended to make EUnetHTA’s cooperation more transparent and to include patient and consumer organizations, healthcare providers, statutory health-insurance payers, and industry representatives in discussion of European HTA work.

• 2021

  Support transition toward the EU HTA systemStrategy

  Background

  European institutions and national authorities were preparing for a more structured system of cooperation under the EU HTA Regulation.

  Action taken

  EUnetHTA 21 was established to build on earlier Joint Actions, apply their lessons, and support the future European Union HTA system.

  Aftermath

  The programme represented a transition from mainly voluntary network cooperation toward support for a future EU-level HTA framework.

  Source

• 2016

  Increase the use and efficiency of joint HTA workStrategy

  Background

  European HTA cooperation required broader practical use and stronger quality and efficiency in joint outputs.

  Action taken

  Joint Action 3 focused on increasing the use, quality, and efficiency of joint HTA work at European level.

  Aftermath

  The programme’s experience and outputs were carried forward into EUnetHTA 21 and discussions around a future EU HTA system.

  Source

• 2012

  Adopt a strategy for sustainable European HTA collaborationStrategy

  Background

  The conclusion of the first Joint Action created a need to move from initial network formation toward a durable model for cooperation among European HTA bodies.

  Action taken

  Joint Action 2 continued the work and developed a general strategy, common principles, and an implementation proposal for sustainable collaboration, in the context of European cross-border healthcare policy.

  Aftermath

  The work provided a foundation for later Joint Actions and for the development of more structured European cooperation on HTA.

  Source

1. 1European Network for Health Technology Assessmenten.wikipedia.org
2. 2European Network for Health Technology Assessment official websiteeunethta.eu